NCT03929029 2026-01-05Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaDana-Farber Cancer InstitutePhase 1 Active not recruiting11 enrolled 11 charts
NCT06218511 2025-12-22A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)National Cancer Institute, NaplesPhase 1 Active not recruiting10 enrolled